Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication

Lukas Schuierer, Michael Gebhard, Hans Georg Ruf, Ulrich Jaschinski, Thomas M. Berghaus, Michael Wittmann, Georg Braun, Dirk H. Busch, Reinhard Hoffmann

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Background: Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high proportion of ventilated intensive care unit (ICU) patients. However, the clinical significance remains poorly defined. We investigated whether patients with ventilator-associated pneumonia not responding to antibiotics and in whom high levels of HSV could be detected in respiratory secretions benefit from acyclovir treatment. Methods: Respiratory secretions (bronchoalveolar lavage fluid or tracheal aspirates) were tested for HSV replication by quantitative real-time PCR. ICU survival times, clinical parameters, and radiographic findings were retrospectively compared between untreated and acyclovir treated patients with high (> 105 HSV copies/mL) and low (103-105 HSV copies/mL) viral load. Results: Fifty-seven low and 69 high viral load patients were identified. Fewer patients with high viral load responded to antibiotic treatment (12% compared to 40% of low load patients, p = 0.001). Acyclovir improved median ICU survival (8 vs 22 days, p = 0.014) and was associated with a significantly reduced hazard ratio for ICU death (HR = 0.31, 95% CI 0.11-0.92, p = 0.035) in high load patients only. Moreover, circulatory and pulmonary oxygenation function of high load patients improved significantly over the course of acyclovir treatment: mean norepinephrine doses decreased from 0.05 to 0.02 μg/kg body weight/min between days 0 and 6 of treatment (p = 0.049), and median PaO2/FiO2 ratio increased from 187 to 241 between day 3 and day 7 of treatment (p = 0.02). Chest radiographic findings also improved significantly (p < 0.001). Conclusions: In patients with ventilator-associated pneumonia, antibiotic treatment failure, and high levels of HSV replication, acyclovir treatment was associated with a significantly longer time to death in the ICU and improved circulatory and pulmonary function. This suggests a causative role for HSV in this highly selected group of patients.

Original languageEnglish
Article number12
JournalCritical Care
Volume24
Issue number1
DOIs
StatePublished - 10 Jan 2020

Keywords

  • Acyclovir
  • Bronchoalveolar lavage fluid
  • Real-time polymerase chain reaction
  • Simplexvirus
  • Ventilator-associated pneumonia

Fingerprint

Dive into the research topics of 'Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication'. Together they form a unique fingerprint.

Cite this